DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

Evogene Ltd.

TASE:EVGN Stock Report

Market Cap: ₪23.8m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Evogene Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ofer Haviv

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure21.8yrs
CEO ownershipn/a
Management average tenure2.6yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Analysis Article • Mar 05

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 09

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 26

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 13

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 07

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jun 16

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Mar 02

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 28

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Evogene ( TLV:EVGN ) stock...
Analysis Article • Jan 21

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Evogene ( TLV:EVGN ) stock is...
Analysis Article • Nov 30

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Ofer Haviv has been the CEO of Evogene Ltd. (TLV:EVGN) since 2004, and this article will examine the executive's...

CEO Compensation Analysis

How has Ofer Haviv's remuneration changed compared to Evogene's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$18m

Mar 31 2026n/an/a

-US$19m

Dec 31 2025n/an/a

-US$14m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$13m

Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$424kUS$374k

-US$13m

Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$401kUS$390k

-US$20m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$25m

Dec 31 2022US$464kUS$415k

-US$27m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$530kUS$420k

-US$28m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$592kUS$367k

-US$23m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$538kUS$366k

-US$18m

Compensation vs Market: Insufficient data to establish whether Ofer's total compensation is reasonable compared to companies of similar size in the IL market.

Compensation vs Earnings: Ofer's compensation has increased whilst the company is unprofitable.


CEO

Ofer Haviv (60 yo)

21.8yrs
Tenure
US$424,000
Compensation

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...


Leadership Team

NamePositionTenureCompensationOwnership
Ofer Haviv
CEO, President21.8yrsUS$424.00kno data
Yoash Zohar
Chief Executive Officer of Casterra Ag Ltd.2.7yrsUS$583.00kno data
Dan Gelvan
Chief Executive Officer of Ag Plenus Ltd.2.6yrsUS$369.00kno data
Ilia Zhidkov
Chief Technology Officerless than a yearno data0%
₪ 0
Liat Wejgman
Vice President of Human Resources4.7yrsno datano data
Gabi Tarcic
Chief Development Officerless than a yearno data0.0083%
₪ 2.0k
2.6yrs
Average Tenure
59yo
Average Age

Experienced Management: EVGN's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ofer Haviv
CEO, President1.5yrsUS$424.00kno data
Dan Falk
Independent Director4.8yrsno data0%
₪ 0
Nir Nimrodi
Independent Chairman4yrsno data0%
₪ 0
Leon Recanati
Independent Director21.3yrsno data9.93%
₪ 2.4m
Yael Margolin
Directorno datano datano data
Yoshinori Oikawa
Directorno datano datano data
Sarit Weiss-Firon
Independent Director10.1yrsno data0%
₪ 0
John Irwin
Member of Scientific Advisory Boardless than a yearno datano data
Adrian Percy
Independent Director7.6yrsno data0%
₪ 0
Dan Major
Member of Scientific Advisory Boardless than a yearno datano data
2.8yrs
Average Tenure
61yo
Average Age

Experienced Board: EVGN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/12 04:55
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evogene Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
David BegleiterDeutsche Bank
Hoonshik YangOppenheimer & Co. Inc.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide